Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction

Area of Science:

• Biochemistry
• Oncology
• Vascular Biology

Background:

• Targeting tumor vasculature is a key strategy in cancer therapy.
• Tissue Factor (TF) plays a critical role in blood coagulation.
• Previous approaches have focused on TF's pro-coagulant activity for tumor treatment.

Purpose of the Study:

• To investigate the anti-tumor potential of a novel fusion protein, tTF-CREKA.
• To evaluate the thrombogenic activity of tTF-CREKA when targeted to tumor cells.
• To assess the efficacy of tTF-CREKA in inhibiting tumor growth in vivo.

Main Methods:

• Constructed a fusion protein (tTF-CREKA) combining truncated human Tissue Factor (tTF) with a tumor-targeting pentapeptide (CREKA).
• Administered tTF-CREKA systemically to tumor-bearing mice.
• Assessed tumor-selective intravascular thrombosis, tumor blood perfusion, and tumor growth inhibition.

Main Results:

• tTF-CREKA selectively targeted tumor vasculature, restoring TF's coagulation-inducing activity.
• Systemic administration led to tumor-selective intravascular thrombosis.
• Reduced tumor blood perfusion and significantly inhibited tumor growth.

Conclusions:

• tTF-CREKA demonstrates potent anti-tumor activity by inducing tumor-selective thrombosis.
• This fusion protein represents a promising new therapeutic strategy for solid tumors.
• Targeting tumor blood supply via engineered TF fusion proteins offers a novel treatment modality.